Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight (New England Journal of Medicine)